Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
复制标题
DOI：
10.1200/jco.20.00714
复制
发表时间：
2020-10-20
影响因子：
45.3
通讯作者：
Kunitz, Annegret
中科院分区：
文献类型：
--
作者：
Gruenwald, Viktor;Karch, Annika;Kunitz, Annegret
阿霉素是晚期、不能手术的软组织肉瘤（STS）患者的标准治疗。我们测试了帕唑帕尼是否具有疗效与多柔比星在老年患者的STS和提供上级耐受性血液toxicity. Patients和METHODS患者年龄60岁或以上，没有以前的系统治疗进展性晚期或转移性STS谁有东部肿瘤协作组性能状态0至2和足够的器官功能。治疗包括帕唑帕尼800毫克，每天一次或阿霉素75毫克/平方米，每3周一次（
PURPOSEDoxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that of doxorubicin in elderly patients with STS and offers superior tolerability for hematologic toxicity.PATIENTS AND METHODSPatients age 60 years or older without previous systemic treatment for progressive advanced or metastatic STS who had Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were included. Treatment consisted of pazopanib 800 mg once per day or doxorubicin 75 mg/m(2) once every 3 weeks (